Oral News and Research

RSS

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

A UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.

19 Feb 2010

ARYx Therapeutics retains Cowen's services to optimize late-stage asset value

ARYx Therapeutics Inc., a biopharmaceutical company, today announced that it has retained Cowen and Company to explore strategic options for ARYx.

19 Feb 2010

Lower dose of avosentan drug may provide more favorable results in diabetes patients

The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

18 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Ventas reports 7.8% increase in normalized FFO for year ended December 31, 2009

Ventas, Inc. said today that normalized Funds From Operations (“FFO”) for the year ended December 31, 2009 increased 7.8 percent to $409.0 million, from $379.5 million for the comparable 2008 period.

18 Feb 2010

Acute sinus infections always begin as cold

Have a cold that just won't go away or is getting worse? Chances are your cold has developed into a sinus infection - a common problem this time of year, says Alan Wild, M.D., assistant professor of otolaryngology at Saint Louis University School of Medicine.

18 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

The U.S. Food and Drug Administration today warned consumers about the potential for serious side effects from mistakenly using Maalox Total Relief instead of other Maalox products. The two products are intended for the relief of different symptoms and contain different active ingredients.

18 Feb 2010

PDA emphasizes the importance of developing healthy teeth and gums at early age

It's National Children's Dental Health Month, an oral health campaign designed to educate children about the importance of good oral health. The Pennsylvania Dental Association emphasizes developing good habits at an early age to help children get a good start on a lifetime of healthy teeth and gums.

18 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

Feeding preterm infants in response to hunger and satiation cues may allow earlier hospital discharge

Although many parents and health care providers attempt to schedule a preterm newborn's feeding pattern, a new review of studies reveals that feeding in response to the infant's own hunger cues might result in earlier discharge from the hospital.

18 Feb 2010

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.

17 Feb 2010

Fourth-quarter and full-year 2009 results announced by Celsion

Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.

17 Feb 2010

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Cannabis Science Inc., an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who responded to our PTSD survey. The survey is still available for a limited time online on the www.cannabisscience.com website for all those who still wish to participate.

17 Feb 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

UKONS publishes position statement on safe, effective use of oral anticancer medicines

A position statement from the UK Oncology Nursing Society (UKONS) on the safe, effective use of oral anticancer medicines was published online on 5 February 2010 by ecancermedicalscience.

17 Feb 2010

Study demonstrates usefulness of salivary diagnostics in finding pancreatic cancer

The good news is that there may soon be a new weapon in the battle against the so-called "worst" cancer - cancer of the pancreas. A multidisciplinary group of investigators from the UCLA School of Dentistry, the David Geffen School of Medicine at UCLA, the UCLA School of Public Health and UCLA's Jonsson Comprehensive Cancer Center has demonstrated the usefulness of salivary diagnostics in the effort to find and fight the disease.

17 Feb 2010

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010.

17 Feb 2010

Study shows value-based plans can improve adherence for diabetes medicines

A study by CVS Caremark (NYSE: CVS), published this week in the American Journal of Pharmacy Benefits, finds that insurance benefit designs that reduce the cost of medications for plan participants result in patients being more likely to start and stay on their medication therapy.

17 Feb 2010

Oral News and Research

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

ARYx Therapeutics retains Cowen's services to optimize late-stage asset value

Lower dose of avosentan drug may provide more favorable results in diabetes patients

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Ventas reports 7.8% increase in normalized FFO for year ended December 31, 2009

Acute sinus infections always begin as cold

Incyte announces 2009 financial results and key fourth-quarter accomplishments

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

PDA emphasizes the importance of developing healthy teeth and gums at early age

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Genzyme announces fourth-quarter and full-year 2009 financial results

Feeding preterm infants in response to hunger and satiation cues may allow earlier hospital discharge

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Fourth-quarter and full-year 2009 results announced by Celsion

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

UKONS publishes position statement on safe, effective use of oral anticancer medicines

Study demonstrates usefulness of salivary diagnostics in finding pancreatic cancer

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

Study shows value-based plans can improve adherence for diabetes medicines

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News